Insider Buying: Tandem Diabetes Care Inc (TNDM) CEO Purchases 750,000 Shares of Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) CEO Kim D. Blickenstaff acquired 750,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was purchased at an average price of $2.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tandem Diabetes Care Inc (NASDAQ:TNDM) traded up $0.02 during trading hours on Tuesday, hitting $2.43. The stock had a trading volume of 837,794 shares, compared to its average volume of 923,213. Tandem Diabetes Care Inc has a 1-year low of $2.14 and a 1-year high of $26.00. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The company has a market cap of $23.78, a price-to-earnings ratio of -0.12 and a beta of 0.44.

Several large investors have recently bought and sold shares of TNDM. Wedbush Securities Inc. boosted its position in shares of Tandem Diabetes Care by 88.6% in the 3rd quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after purchasing an additional 88,709 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Tandem Diabetes Care by 13.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock worth $482,000 after purchasing an additional 78,748 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after purchasing an additional 32,991 shares during the last quarter.

TNDM has been the topic of several recent research reports. Zacks Investment Research lowered Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Robert W. Baird restated a “hold” rating and issued a $3.00 price target on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $11.29.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/13/insider-buying-tandem-diabetes-care-inc-tndm-ceo-purchases-750000-shares-of-stock.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply